Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced completion of enrollment for its phase-2 PoC clinical study evaluating the safety and efficacy of samelisant in adult narcolepsy patients with and without cataplexy. Data readout for the study is anticipated in second quarter of FY2024.

"We are pleased to have achieved this milestone with the development of samelisant in the narcolepsy space and look forward to the data readout in second quarter of FY2024".

"Narcolepsy is a chronic disease characterized by the symptoms such as excessive daytime sleepiness (EDS) and cataplexy that impairs quality of life, Samelisant's mechanism of action increases histamine transmission in the brain which provides the scientific rationale for its potential clinical utility for the management of narcolepsy", said Venkat Jasti, Chairman & CEO of Suven Life Sciences.